CanadaBuys #BCPHSA_19229

Direct Award: Supply of Darbepoetin alfa (Aranesp) to PHSA by Amgen Canada Inc.

This opportunity involves a direct contract award for a critical pharmaceutical supply in the Canadian healthcare system. - Government Buyer: - Provincial Health Services Authority (PHSA), Canada - OEMs and Vendors: - Amgen Canada Inc. (OEM and supplier) - Products/Services Requested: - Erythropoietin Stimulating Agent: Darbepoetin alfa (Aranesp) - No specific part numbers or quantities provided - Unique or Notable Requirements: - Aranesp (Darbepoetin alfa) will be the only Erythropoietin Stimulating Agent (ESA) available in Canada due to the discontinuation of Janssen Inc.'s epoetin alfa (Eprex) - No biosimilar alternatives are currently approved in Canada - Direct award justified by absence of competition for technical reasons - Vendors may challenge the decision by submitting written objections - Estimated contract value: $83.6 million - Five-year contract term for exclusive supply

Description

The Provincial Health Services Authority (PHSA) intends to directly award a contract to Amgen Canada Inc. for the supply of Erythropoietin Stimulating Agents - Darbepoetin alfa (Aranesp) for a term of five years. The estimated contract value is $83.6 million. This direct award is due to the absence of competition for technical reasons, as Amgen Canada Inc. is the sole supplier of this product in Canada following the discontinuation of a competing product by another supplier. Vendors wishing to challenge this decision must submit a written objection by July 27, 2026.

View original listing